ClinicalTrials.gg
CompletedNCT00761358Updated Nov 23, 2010

To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia

A Phase 3 interventional study of Z-338 and Placebo in Functional Dyspepsia, sponsored by Zeria Pharmaceutical. Completed at 2 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2010-11-23.

Sponsored by Zeria Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
820
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.

Planned enrollment
Largest of 11
820 · median 282
Started
2008
with 1 other
Phase 3
4 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
7 of 11
Zeria Pharmaceutical

Among the 11 studies testing Z 338 in Dyspepsia, this one has the largest planned enrollment, is one of 2 that started in 2008, is one of 4 in phase 3, and was the 6th registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:

About Z 338

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Z 338 in Dyspepsia, or all of them as a file.
02

Study summary

The purpose of this study is to verify the superior efficacy of Z-338 to placebo in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

Keywords

  • Acotiamide
04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects showing at least one of the 4 symptoms (upper abdominal pain, upper abdominal discomfort, epigastric pain, epigastric burning) for at least 6 months before obtaining
  • Subjects showing two or more of the following symptoms: upper abdominal pain, upper abdominal discomfort, post-prandial fullness, upper abdominal bloating, early satiety, nausea, vomiting and/or excessive belching for at least 3 months (one of them should be post-prandial fullness or early satiation)
  • Bothersome symptoms should be post-prandial fullness, upper abdominal bloating or early satiety at the time of obtaining informed consent

Exclusion criteria

Exclusion Criteria:

  • Subjects with structural disease that is likely to explain the symptom (e.g., GERD, erosion, ulcer, hiatal hernia, bleeding, or Barrett's esophagus) confirmed by upper endoscopy at the obtaining
  • Subjects have heartburn in last 12 weeks before obtaining informed consent
  • Subjects with irritable bowel disease (IBS)
  • Subjects with diabetes mellitus requiring treatment
  • Subjects with serious anxiety disorder
  • Subjects with depression and/or sleep disorder
  • Subjects with biliary tract disease and/or pancreatitis (including chronic pancreatitis)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
820 participants (estimated)

Study arms

  • Experimental
    Z-338

    Drug: Z-338

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • DrugZ-338

    Oral

  • DrugPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. General impression at last visit in treatment period

    Time frame: 4 week

  2. Elimination rate of post-prandial fullness, upper abdominal bloating and early satiety at last visit in treatment period

    Time frame: 4 week

Secondary outcomes

  1. Individual symptom score

    Time frame: Every week

  2. SF-NDI

    Time frame: At 0, 4 week and 4 week after treatment

  3. General Impression

    Time frame: Every week

  4. Laboratory tests

    Time frame: At 0, 4 week and 4 week after treatment

  5. Adverse Event

    Time frame: 4 week treatment period and 4 week after treatment

07

Study locations

2 sites
  • Hokkaido, Japan
  • Tokyo, Japan
08

References and documents

Publications

  • Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012 Jun;61(6):821-8. doi: 10.1136/gutjnl-2011-301454. Epub 2011 Dec 9. PubMed 22157329 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Jun 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 29, 2008
Start
Sep 2008
Primary completionActual
Jun 2010
CompletionActual
Aug 2010
Last update
Nov 23, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00761358
First posted
Sep 29, 2008
Start date
Sep 2008
Primary completion
Jun 2010
Completion
Aug 2010
Last update
Nov 23, 2010

Study contacts

Michio Hongo, Professor
study director · Tohoku University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion